APAF1 contains several important domains:
Upon binding to cytochrome c and dATP, APAF1 undergoes a conformational change that allows it to oligomerize and form the apoptosome, a large quaternary protein structure. The apoptosome then recruits and activates procaspase-9, which in turn activates the executioner caspases, leading to apoptosis .
The APAF1 interacting protein (Human Recombinant) is a synthetic version of the naturally occurring protein that interacts with APAF1. This interaction is crucial for the formation and function of the apoptosome. The recombinant version is produced using recombinant DNA technology, which involves inserting the gene encoding the APAF1 interacting protein into a suitable expression system, such as bacteria or yeast, to produce the protein in large quantities.
The interaction between APAF1 and its interacting proteins is vital for the regulation of apoptosis. Dysregulation of apoptosis can lead to various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Therefore, understanding the interactions of APAF1 is crucial for developing therapeutic strategies for these conditions .
Recombinant APAF1 interacting protein is widely used in research to study the mechanisms of apoptosis. It is also used in drug discovery and development, as targeting the apoptotic pathway is a promising strategy for treating diseases characterized by either excessive or insufficient apoptosis.